Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with Systemic Sclerosis

Journal of Biological Regulators and Homeostatic Agents

Volumn 23, Issue 1, 2009, Pages 23-29

  Rosato, E ^a   Letizia, C ^a   Proietti, M ^a   Aversa, A ^a   Menghi, G ^a   Rossi, C ^a   Torella, E ^a   Cotesta, D ^a   Petramala, L ^a   Bruzziches, R ^a   Spera, G ^a   Pisarri, S ^a   Salsano, Felice ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adrenomedullin; Endothelin 1; Phosphodiesterase type 5; Phosphodiesterase type 5 inhibitor; Raynaud's phenomenon; Systemic Sclerosis

Indexed keywords

ACETYLCYSTEINE; ADRENOMEDULLIN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; TADALAFIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE DURATION; DRUG EFFECT; HUMAN; MALE; OPEN STUDY; PROTEIN BLOOD LEVEL; RAYNAUD PHENOMENON; SYSTEMIC SCLEROSIS;

ADRENOMEDULLIN; ADULT; CARBOLINES; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN-1; FEMALE; HUMANS; MALE; PHOSPHODIESTERASE INHIBITORS; RAYNAUD DISEASE; SCLERODERMA, SYSTEMIC;

EID: 64249123733     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. LeRoy EC, Black C, Fleishmaier R, Jblonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1998; 15:202-5.
2. Livi R, Teghini L, Generini S, Matucci-Cerinic M. The loss of endothelium-dependent vascular tone control in systemic sclerosis. Chest 2001; 119:672-3.
3. Kawaguchi Y, Suzuki K, Hara M, Hidaka T, Ishizuka T, Kawagoe M, Nakamura H. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53:506-10.
4. Salsano F, Letizia C, Proietti M, Rossi C, Proietti AR, Rosato E, Pisarri S. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynaud's phenomenon. Int J Immunopathol Pharmacol 2005; 18:761-70.
5. Letizia C, Danese C, D'Erasmo E. Increased plasma adrenomedullin concentrations in patients with Raynaud's phenomenon. J Rheumatol 1999; 26:759-60.
6. Ibba-Manneschi L, Niissalo S, Milia AF, Allanore Y, Del Rosso A, Pacini A, et al. Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis Rheum 2006; 54:202-13.
7. Allanore Y, Borderie D, Hilliquin P, Hernvann A, Levacher M, Lemarechal H, et al. Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology (Oxford) 2001; 40:1089-96.
8. Mok MY, Cheung BM, Lo Y, Leung RY, Wong WS, Lau CS. Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis. J Rheumatol 2007; 34:2224-9.
9. Eto T. A review of the biological properties and clinical implications of adrenomedullin and proadrenomedullin N-terminal 20 peptide (PAMP), hypotensive and vasodilating peptides. Peptides 2001; 22:1693-711.
10. Ishiyama Y, Kitamura K, Ichiki Y, Nakamura S, Kida O, Kangawa K, et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharrnacol 1993; 241:271-3.
11. Kahaleh MB. Endothelin, an endothelial dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis Rheum 1991; 34: 978-83.
12. Yanagisawa M, Kurihara H, Kimura S, Goto K, Masaki T. A novel peptide vasoconstrictor, endothelin, is produced by vascular endothelium. and modulates smooth muscle Ca2+ channels. J Hypertens Suppl 1988; 6:188-91.
13. Marczin N, Riedel B, Royston D, Yacoub M. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis. Lancet 1998; 352:405-6.
14. Wigley FM. Clinical practice: Raynaud's phenomenon. N Engl J Med 2002; 347:1001-8.
15. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 2005; 112:2980-5.
16. Wilkens H, Guth A, König J, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-22.
17. Ghofrani HA, Wiedemann R, Rose et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515-22.
18. Zhao L, Mason NA, Morrell NW, et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001; 104: 424-8.
19. Proietti M, Aversa A, Letizia C, Rossi C, Menghi G, Bruzziches R, et al. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 2007; 34: 1712-7.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Dignostic and Therapeutic Criteria Committee. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
21. Medseger TA, Bombardieri S, Czirjak L, Scorza R, Della Rossa A, Bencivelli W. Assessment of severity and prognosis. Clin Exp Rehumatol 2003; 21(S)29: 42-6.
22. Valentini G, Silman AJ, Veale D. Assessment of disease activity. Clin Exp Rheumatol 2003; 21(S)29: 39-41.
23. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999; 11:319-26.
24. Valentini G, Della Rossa A, Bombardieri S, Bencivelli W, Silman AJ, D'Angelo S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60:592-8.
25. Vizza CD, Letizia C, Badagliacca R, Sciomer S, Poscia R, Della Rocca G, et al. Plasma adrenomedullin and endothelin-1 concentration during low-dose dobutamine infusion: Relationship between pulmonary uptake and pulmonary vascular pressure/flow characteristics. Regul Pept 2006; 136: 85-91.
26. Hinson JP, Thomson LM, Kapas S. Adrenomedullin and CGRP receptors mediate different effects in the rat adrenal cortex. Endocr Res 1998; 24:725-8.
27. Nanke Y, Kotake S, Akama H, Shimamoto K, Hara M, Kamatani N. Raised plasma adrenomedullin patients with systemic sclerosis complicated by pulmonary hypertension. Ann Rheum Dis 2000; 59: 493-4.
28. Letizia C, Centanni M, Scuro L, Canettieri GL, Cerci S, De Crocchis A, et al. High Plasma Levels of Endothelin-1 in untreated Addison's Disease. Eur J Endocrinol 1996; 135:696-9.
29. Biondi ML, Marasini B, Bassani C, Agostoni A. Increased plasma endothelin levels in patients with Raynaud's phenomenon. N Engl J Med 1991; 324: 1139-40.
30. Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H, et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.
31. Humbert M, Simonneau G. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases. Nat Clin Pract Rheumatol 2005; 1:93-101.
32. Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis. Ann Rheum Dis 2007; 66:1398-9.
33. Scheiner-Bobis G, Eva A, Kirch U. Signalling pathways involving sodium pump stimulate endothelin-1 secretion and nitric oxide production in endothelial cells. Cell Mol Biol 2006; 52:58-63.
34. Dai ZK, Tan MS, Chai CY, Chou SH, Lin PC, Yeh JL, et al. Effects of sildenafil on pulmonary hypertension and levels of ET-1, eNOS, and cGMP in aorta-banded rats. Exp Biol Med 2006; 231:942-7.
35. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007; 19:200-7.